Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Yitao ZhengYan-Jun XiangHongqi ShiZhuoqun LinShuqun ChengJiuting ZhuPublished in: Journal of hepatocellular carcinoma (2024)
In treating intermediate-stage HCC, the survival benefit of combining TACE with atezolizumab and bevacizumab was significantly higher than TACE alone, and the treatment was well-tolerated.